Last reviewed · How we verify
UFH
UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin.
UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | UFH |
|---|---|
| Also known as | Unfractionated Heparin |
| Sponsor | VarmX B.V. |
| Drug class | Low molecular weight heparin |
| Target | Antithrombin III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
UFH is a heparin-based anticoagulant that works by binding to antithrombin III, which in turn inhibits the activity of Factor Xa and thrombin. This leads to a decrease in the formation of blood clots and an increase in the breakdown of existing clots.
Approved indications
- Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism
- Atrial fibrillation for stroke prevention
Common side effects
- Bleeding
- Hypersensitivity reactions
- Osteoporosis
Key clinical trials
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia (PHASE2)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial (NA)
- HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
- Accuracy and Reliability of Artificial Intelligence Cephalometric Analysis Software Compared to Manual Tracing
- Comparison of Two Pulmonary Embolism Treatments (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UFH CI brief — competitive landscape report
- UFH updates RSS · CI watch RSS
- VarmX B.V. portfolio CI